Savara Inc. reports a three-month U.S. Food and Drug Administration review extension for molgramostim in autoimmune PAP, shifting the PDUFA date to November 22, 2026 from the previously set August 22, 2026.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
U.S. Food and Drug Administration has extended the review timeline for Savara’s biologics license application (BLA) for molgramostim in autoimmune pulmonary alveolar proteinosis (PAP) by three months, setting a new PDUFA action date of November 22, 2026.
Savara had previously disclosed in its February 20 press release that the FDA accepted the BLA for Priority Review and assigned an original PDUFA target action date of August 22, 2026.
The application remains under Priority Review. According to the agency, Savara’s recent submissions in response to information requests were classified as a major amendment, triggering the extension.
Importantly, the FDA did not raise concerns related to safety, efficacy, or manufacturing in its communication. The additional time will allow completion of the review, including evaluation of newly submitted materials.
Molgramostim has received multiple regulatory designations reflecting its potential in a rare disease setting. These include Fast Track and Breakthrough Therapy designations in the United States, Orphan Drug status from both the FDA and the European Medicines Agency, and Innovation Passport and Promising Innovative Medicine designations from the U.K.’s Medicines and Healthcare Products Regulatory Agency.
Disease Background: Autoimmune PAP
Autoimmune pulmonary alveolar proteinosis is a rare respiratory disorder marked by accumulation of surfactant within the alveoli. Surfactant, composed of lipids and proteins, normally prevents alveolar collapse and is continuously cleared by immune cells known as alveolar macrophages.
In autoimmune PAP, this clearance mechanism fails. Autoantibodies neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF), a key signaling molecule required for macrophage function. Without GM-CSF activity, macrophages cannot effectively remove excess surfactant, leading to its buildup.
This accumulation disrupts gas exchange and leads to symptoms such as shortness of breath, persistent cough, and fatigue. Patients may also experience fever, chest pain, or hemoptysis, particularly when secondary infections occur. Over time, the disease can progress to severe complications, including lung fibrosis and, in advanced cases, the need for lung transplantation.
Regulatory Outlook
The FDA’s decision to extend the review reflects procedural requirements rather than concerns about the therapy’s profile. The revised timeline positions late 2026 as a key milestone for molgramostim, as regulators complete their assessment of its potential role in addressing an unmet need in autoimmune PAP.
Reference
About the Writer
Chikkula Pavan Kumar, Pharm.D is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.